1H-吲哚-2-丙酸 | 5836-08-8

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吲哚及其衍生物
• 中文名称: 1H-吲哚-2-丙酸
• 英文名称: indole-2-propionic acid
• 英文别名: indole-3-propionic acid；indole propionic acid；3-(indol-2-yl)propanoic acid；3-(1H-indol-2-yl)propanoic acid；3-(Indol-2-yl)-propionsaeure；3-indol-2-yl-propionic acid；1H-indole-2-propanoic acid；3-indolylpropionic acid
• CAS: 5836-08-8
• 化学式: C₁₁H₁₁NO₂
• 分子量: 189.214
• InChiKey: HLSMPONBWJBOKA-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.9
• 重原子数：
  14
• 可旋转键数：
  3
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.18
• 拓扑面积：
  53.1
• 氢给体数：
  2
• 氢受体数：
  2

安全信息

• 海关编码：
  2933990090

反应信息

• 作为反应物：
  描述：

  1H-吲哚-2-丙酸 在 4-二甲氨基吡啶 、 盐酸-N-乙基-Nˊ-(3-二甲氨基丙基)碳二亚胺 作用下， 以 二氯甲烷 为溶剂， 反应 24.0h， 以80%的产率得到1,2-dihydro-1H-pyrrolo<1,2-a>indol-3-one
  参考文献：
  名称：

  1,2,3,9-四氢-4 H-咔唑-4-一和8,9-二氢吡啶基-[1,2- a ]吲哚-6（7 H）-1 H-吲哚-2-丁酸酸

  摘要：

  由1 H-吲哚-2-丁酸开发了标题环系统的有效合成方法，该方法很容易从2-氟-1-硝基苯分四个步骤。在含甲苯的溶液中加热1 H-吲哚-2-丁酸对甲苯磺酸在110℃下以88％的产率提供了1,2,3,9-四氢-4 H-咔唑-4-酮。将该相同的酸在甲苯中加热，不添加酸，以90％的产率得到8,9-二氢吡啶并[1,2 - a ]吲哚-6（7H）-一。这还可以直接以92％的收率制备四氢4 H-咔唑-4-酮通过在110°C的浓盐酸中与铁进行串联还原-环芳构化-酰化反应，合成6-（2-硝基苯基）-5-氧代己酸甲酯。这种方法在五元和七元环的闭合中的应用也很成功。J.杂环化​​学，（2009）。

  DOI：

  10.1002/jhet.22
• 作为产物：
  描述：

  diethyl 2-[[1-(benzenesulfonyl)-3-phenylsulfanylindol-2-yl]methyl]propanedioate 在 sodium hydroxide 、 Raney Nickel(H) 作用下， 以 乙醇 、 丙酮 为溶剂， 反应 1.0h， 生成 1H-吲哚-2-丙酸
  参考文献：
  名称：

  一种简便的2-烷基吲哚制剂-生物碱的潜在中间体

  摘要：

  用活性亚甲基化合物烷基化后，除去PhS-和PhSO 2-基团得到的溴代化合物提供了标题化合物。

  DOI：

  10.1016/s0040-4039(00)86031-1

文献信息

• NOVEL LOW-MOLECULAR-COMPOUND FOR IMPROVING PRODUCTION, MAINTENANCE AND PROLIFERATION OF PLURIPOTENT STEM CELLS, COMPOSITION COMPRISING THE SAME, AND CULTURE METHOD
  申请人：KOREA RESEARCH INSTITUTE OF BIOSCIENCE AND BIOTECHNOLOGY

  公开号：US20150159142A1

  公开（公告）日：2015-06-11

  According to the present invention, when the novel low-molecular-weight compound RSC-133 is added in a culture process for producing reprogrammed pluripotent stem cells from human differentiated cells, it can increase the efficiency of reprogramming and can significantly reduce the time required for the induction of reprogramming. Particularly, the novel compound RSC-133 can substitute for c-Myc acting as both a reprogramming factor and an oncogenic factor, and it can effectively increase the efficiency of reprogramming in both normal oxygen culture conditions and hypoxic culture conditions. In addition, RSC-133 can inhibit the induction of aging occurring in the reprogramming process, exhibits the effect of promoting cell proliferation, and induces epigenetic activation to improve culture conditions for induction of reprogramming. The present invention will contribute to optimizing a process of producing induced pluripotent stem cells from a small amount of patient-specific somatic cells obtained from various sources, and thus it will significantly improve a process of developing clinically applicable personalized stem cell therapy agents and new drugs and will facilitate the practical use of these agents and drugs. In addition, the novel low-molecular-weight compound RSC-133 can provide a cell culture medium effective for maintaining the undifferentiated state of human embryonic stem cells that are typical pluripotent stem cells. The medium composition containing RSC-133 can effectively induce the proliferation of human embryonic stem cells in an undifferentiated state and can be effectively used for the development of a system for culturing large amounts of embryonic stem cells.

  根据本发明，当在从人类分化细胞生产重编程的多能干细胞的文化过程中添加新型的低分子量化合物RSC-133时，它可以提高重编程的效率，并且可以显著减少诱导重编程所需的时间。特别是，新型化合物RSC-133可以替代作为重编程因子和致癌因子的c-Myc，并且可以在正常氧文化条件和无氧文化条件下有效地提高重编程的效率。此外，RSC-133可以抑制在重编程过程中发生的衰老诱导，表现出促进细胞增殖的效果，并诱导表观遗传激活以改善重编程诱导的培养条件。本发明将有助于优化从各种来源获得的患者特异性体细胞的小量生产诱导多能干细胞的过程，从而将显著改进开发临床应用的个人化干细胞治疗剂和新药的过程，并将促进这些剂和药物的实用化。另外，新型的低分子量化合物RSC-133可以提供一个有效的细胞培养介质，用于维持典型多能干细胞的人胚胎干细胞的不分化状态。含有RSC-133的培养基质可以有效诱导人胚胎干细胞在不分化状态的增殖，并且可以有效地用于大量胚胎干细胞培养系统的开发。
• CYCLIC AMIDE DERIVATIVES AS INHIBITORS OF 11 - BETA - HYDROXYSTEROID DEHYDROGENASE AND USES THEREOF
  申请人：CONNEXIOS LIFE SCIENCES PVT. LTD.

  公开号：US20150158860A1

  公开（公告）日：2015-06-11

  The present invention relates to certain amide derivatives that have the ability to inhibit 11-β-hydroxysteroid dehydrogenase type 1 (11β-HSD-1) and which are therefore useful in the treatment of certain disorders that can be prevented or treated by inhibition of this enzyme. In addition the invention relates to the compounds, methods for their preparation, pharmaceutical compositions containing the compounds and the uses of these compounds in the treatment of certain disorders. It is expected that the compounds of the invention will find application in the treatment of conditions such as non-insulin dependent type 2 diabetes mellitus (NIDDM), insulin resistance, obesity, impaired fasting glucose, impaired glucose tolerance, lipid disorders such as dyslipidemia, hypertension and as well as other diseases and conditions.

  本发明涉及某些酰胺衍生物，这些衍生物具有抑制11-β-羟基类固醇脱氢酶1型（11β-HSD-1）的能力，因此在预防和治疗可以通过抑制该酶来预防或治疗的某些疾病中是有用的。此外，发明还涉及这些化合物的制备方法、含有这些化合物的药物组合物以及这些化合物在治疗某些疾病中的用途。预计本发明的化合物将在治疗非胰岛素依赖型2型糖尿病（NIDDM）、胰岛素抵抗、肥胖、空腹血糖受损、葡萄糖耐量受损、脂质紊乱（如血脂异常）、高血压以及其他疾病和状况中找到应用。
• [EN] CYCLIC AMIDE DERIVATIVES AS INHIBITORS OF 11 - BETA - HYDROXYSTEROID DEHYDROGENASE AND USES THEREOF<br/>[FR] DÉRIVÉS D'AMIDE CYCLIQUES À UTILISER EN TANT QU'INHIBITEURS DE 11-BÊTA-HYDROXYSTÉROÏDE DÉSHYDROGÉNASE ET UTILISATIONS DE CEUX-CI
  申请人：CONNEXIOS LIFE SCIENCES PVT LTD

  公开号：WO2013128465A1

  公开（公告）日：2013-09-06

  The present invention relates to certain amide derivatives that have the ability to inhibit 11-β-hydroxysteroid dehydrogenase type 1 (11β-HSD-1) and which are therefore useful in the treatment of certain disorders that can be prevented or treated by inhibition of this enzyme. In addition the invention relates to the compounds, methods for their preparation, pharmaceutical compositions containing the compounds and the uses of these compounds in the treatment of certain disorders. It is expected that the compounds of the invention will find application in the treatment of conditions such as non-insulin dependent type 2 diabetes mellitus (NIDDM), insulin resistance, obesity, impaired fasting glucose, impaired glucose tolerance, lipid disorders such as dyslipidemia, hypertension and as well as other diseases and conditions.

  本发明涉及某些酰胺衍生物，这些衍生物具有抑制11-β-羟基类固醇脱氢酶1型（11β-HSD-1）的能力，因此在预防或治疗可通过抑制该酶来预防或治疗的某些疾病中是有用的。此外，本发明还涉及这些化合物的制备方法、含有这些化合物的药物组合物以及这些化合物在治疗某些疾病中的用途。预计本发明的化合物将用于治疗非胰岛素依赖型2型糖尿病（NIDDM）、胰岛素抵抗、肥胖、空腹血糖受损、葡萄糖耐量受损、脂质紊乱（如血脂异常）、高血压以及其它疾病和状况。
• Hydrazide and alkoxyamide angiogenesis inhibitors
  申请人：——

  公开号：US20020002152A1

  公开（公告）日：2002-01-03

  Compounds having the formula 1 are methionine aminopeptidase type 2 (MetAP2) inhibitors and are useful for inhibiting angiogenesis. Also disclosed are MetAP2-inhibiting compositions and methods of inhibiting angiogenesis in a mammal.

  具有以下化学式的化合物是蛋氨酸氨肽酶2型（MetAP2）抑制剂，对抑制血管生成有用。还公开了抑制MetAP2的组合物和在哺乳动物中抑制血管生成的方法。
• CERTAIN (2S)-N-[(1S)-1-CYANO-2-PHENYLETHYL]-1,4-OXAZEPANE-2-CARBOXAMIDES AS DIPEPTIDYL PEPTIDASE 1 INHIBITORS
  申请人：ASTRAZENECA AB

  公开号：US20150210655A1

  公开（公告）日：2015-07-30

  The present disclosure relates to certain (2S)-N-[(1S)-1-cyano-2-phenylethyl]-1,4-oxazepane-2-carboxamide compounds (including pharmaceutically acceptable salts thereof), that inhibit dipeptidyl peptidase 1 (DPP1) activity, to their utility in treating and/or preventing clinical conditions including respiratory diseases, such as asthma and chronic obstructive pulmonary disease (COPD), to their use in therapy, to pharmaceutical compositions containing them and to processes for preparing such compounds.

  本公开涉及某些（2S）-N-[(1S)-1-氰基-2-苯乙基]-1,4-噁唑烷-2-羧酰胺化合物（包括其药用盐），其抑制二肽基肽酶1（DPP1）活性，用于治疗和/或预防包括哮喘和慢性阻塞性肺病（COPD）在内的临床疾病，以及它们在治疗中的用途，含有它们的药物组合物以及制备这类化合物的方法。